Expression analysis of multidrug resistance associated genes in neuroblastomas.

• DOI: 10.3892/or.6.5.1143
• Publication Date: 2014-03-10T03:43:53Z
• Authors: P Bader; F Schilling; M Schlaud; R Girgert; R Handgretinger; T Klingebiel; J Treuner; C Liu; D Niethammer; J F Beck
• Keywords: Gene Expression Regulation, Neoplastic; Neuroblastoma; 03 medical and health sciences; 0302 clinical medicine; Brain Neoplasms; Humans; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistance, Multiple; 3. Good health

In a series of 40 neuroblastomas we analyzed the relative mRNA levels of the MDR associated genes encoding MDR1/P-glycoprotein (MDR1), multidrug resistance associated protein (MRP), lung cancer resistance related protein (LRP) and topoisomerase IIalpha (TOPO IIalpha) by cDNA-PCR. Cyclin A (CYCA) was included to examine cellular proliferation activity. MYCN gene expression was analyzed as it was recently shown to be associated with enhanced MRP gene expression in neuroblastomas. We found that tumors with MYCN gene amplification exhibit significantly increased MYCN and MRP gene expression levels. Tumors with an allelic loss of the chromosomal 1p region showed significant (P<0.05) lower MDR1 gene expression (MDR1: 50+/-29, n=4) than tumors without (MDR1: 117+/-81, P<0.05, n=36). Moreover, significant positive correlations were found for MYCN/TOPO IIalpha (P<0.0001), MYCN/CYCA (P<0.05), TOPO IIalpha/CYCA (P<0.01), MRP/CYCA (P<0.0001) and MRP/LRP (P<0.05). Our results give evidence that MDR in neuroblastomas might be caused by multiple resistance factors and that a higher proliferation rate of neuroblastoma cells possibly based on altered MYCN gene expression is associated with enhanced MRP, CYCA and TOPO IIalpha gene expression.